Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.
about
D-Penicillamine for preventing retinopathy of prematurity in preterm infantsPharmacologic interventions for the prevention and treatment of retinopathy of prematurityEducational paper: do we need neonatal clinical pharmacologists?Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal MiceIGF-I in the clinics: Use in retinopathy of prematurityCOMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY.Fatty acid binding protein 4 deficiency protects against oxygen-induced retinopathy in micePromoting vascular repair in the retina: can stem/progenitor cells help?Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edemaIntravitreal bevacizumab for retinopathy of prematurity as first line or rescue therapy with focal laser treatment. A case series.Influence of the difference of breastfeeding volume on a rat model of oxygen-induced retinopathy.Insulin-like growth factor-1 and anti-vascular endothelial growth factor in retinopathy of prematurity: has the time come?[Current therapeutic options in retinopathy of prematurity].Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future.Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic optionsIncidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity.Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity[Laser treatment or intravitreal VEGF inhibition for aggressive posterior retinopathy of prematurity?].Posterior pole sparing laser photocoagulation combined with intravitreal bevacizumab injection in posterior retinopathy of prematurity.Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective AnalysisRetinopathy of prematurity: New developments bring concern and hope.A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.Buckling surgery and supplemental intravitreal bevacizumab or photocoagulation on stage 4 retinopathy of prematurity eyes.Serum concentrations of vascular endothelial growth factor in relation to retinopathy of prematurity.Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I.Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurityPre-Analytical Parameters Affecting Vascular Endothelial Growth Factor Measurement in Plasma: Identifying Confounders.Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab TreatmentLow dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.The Efficacy of Propranolol in Retinopathy of Prematurity and its Correlation with the Platelet Mass Index.Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone.Cytochrome P450 Oxidase 2C Inhibition Adds to ω-3 Long-Chain Polyunsaturated Fatty Acids Protection Against Retinal and Choroidal Neovascularization.Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.Fzd4 Haploinsufficiency Delays Retinal Revascularization in the Mouse Model of Oxygen Induced RetinopathyFGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Miceω-3 and ω-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases.A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extractionAnti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity
P2860
Q24198241-A958E114-C90F-427B-AF53-7EBABECF3999Q26772889-A43AA78F-EBA9-413C-AD3A-3BD994ED4E34Q27009662-56D981DB-39C8-49F7-83DE-CD2BFB255CEDQ27301339-CC955A57-87E9-4590-8DD3-838F09CEC180Q28070089-86831E71-AF7E-419D-A727-BAB6D4290EE3Q33552891-E1DF1E98-4716-4D33-A868-0852CF5751E7Q33572886-6BC6AE54-106E-426F-8AFE-A11AC8D6F60AQ33585478-9936AAB5-BA63-4E5E-9DC5-07DB54E4C227Q33759212-F40B2244-608B-46BF-B62C-937E9253BC54Q34234070-40C336B5-06F5-43BA-AB54-8F0E4CDF1CB9Q34292389-45B87F43-FD2A-4E3D-910C-D3D6EF0FE48AQ34339456-708F551E-BF42-4F6D-A15F-DA2F4BBCD2DFQ34501395-C98720F4-8532-43C7-BF9A-0A7B1DCF17B2Q34554380-70286C36-9708-4AF1-8364-8B4984591082Q34704214-E2B6B0C1-0E3A-4ABE-885B-18429A95DB43Q34740219-C645D006-1D86-408F-9427-172B137B99EDQ35194800-D6FFC407-C1B1-4C06-A7EC-A85D00C2D66BQ35207113-B21F5210-66D5-404D-990A-C9F2AA0FE082Q35473907-65EE1726-FDF9-436E-8C09-34269A2E5452Q35540660-FB9B9F0B-F307-4F69-A42A-236831950990Q35547787-02D40C63-3E74-49C0-920D-A90324A0FACEQ35553854-FDA89130-F3DB-4FEB-A5FD-5313CDB0A196Q35574624-05F327EF-E70E-49D3-AA0A-8F9B5D554E5BQ35665701-D86D2111-8D6A-42E0-97CD-08CD3EA17ED9Q35743301-82C745BC-B3BB-4C17-A486-62080B2551D7Q35776253-EBCDD4D9-D5E1-42C9-A50D-0A198444D86EQ35846321-5A443957-567B-4F28-A338-1CD66935516AQ35851949-62ABC0FB-3F0F-4361-9707-9C61C089548DQ35884984-2D52B1ED-9D5B-4D1A-A29D-FCB1F738445FQ35905482-148D417F-D0D2-485C-BF5E-AF529C27DC0AQ35969307-58D4D6E8-6BDA-4414-9209-38359638B587Q36040633-0FAFF427-CB1C-4B93-9B8E-D05D1E5B7190Q36052210-24A5BC13-EB07-488B-AF4D-72F6673AB804Q36078137-37F9BD22-E77B-4BBA-9CB3-D567E3E73EA3Q36078573-EA4EC422-9EC8-4190-9EBF-2FBF2BA9354CQ36094613-76198A5C-8EEA-448A-9B9D-18429C2A7638Q36281488-4F629BF2-FE3B-4CED-BF0B-0C12E08025F4Q36374238-A862D33A-4F02-4E35-A2E8-3C26D6FB01DCQ36738575-2C4C6BC8-387A-4A22-A962-B6A62AEBA522Q36752978-3542C9C5-9C7F-4F2F-847C-711E734ABBF0
P2860
Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Serum concentrations of bevaci ...... th retinopathy of prematurity.
@ast
Serum concentrations of bevaci ...... th retinopathy of prematurity.
@en
Serum concentrations of bevacizumab
@nl
type
label
Serum concentrations of bevaci ...... th retinopathy of prematurity.
@ast
Serum concentrations of bevaci ...... th retinopathy of prematurity.
@en
Serum concentrations of bevacizumab
@nl
prefLabel
Serum concentrations of bevaci ...... th retinopathy of prematurity.
@ast
Serum concentrations of bevaci ...... th retinopathy of prematurity.
@en
Serum concentrations of bevacizumab
@nl
P2093
P921
P1476
Serum concentrations of bevaci ...... th retinopathy of prematurity.
@en
P2093
Chiharu Iwahashi-Shima
Hitomi Arahori
Kazuko Wada
Kenji Imoto
Noriyuki Kuno
Shunji Kusaka
Tatsuhiko Sato
P304
327-333.e1
P356
10.1016/J.AJO.2011.07.005
P407
P577
2011-09-17T00:00:00Z